NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Immuneering Corp. IMRX
6 fiscal years on record · USD · FY2025 reported · SEC filings only
$-56.0M
$-45.5M
Growth
—
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -53.5
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -16325.8% · Net -15937.3%
ROE
FY2025 · ROE -43.1%
Each USD of equity lost 43 cents this year.
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | · | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | · | · | · | −0.0 | · |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.27 | −2.04 | −1.88 | −1.91 | −2.46 | −3.44 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | −43.1 | −92.5 | −53.4 | −38.0 | −50.2 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 67 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020